Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative medications work by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these substances enhance insulin production and reduce glucagon

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in their